Dominic Cuthbert

UK biotech, Oxford Drug Design (ODD), has secured more than £8 million to help develop new antibiotics effective against drug-resistant superbugs. £5 million of the...

Gilead Sciences is partnering with Nurix Therapeutics to discover, develop and commercialise a pipeline of innovative targeted protein degradation drugs for patients with cancer...

Japan’s Ricoh Company will work with US company Elixirgen Scientific to develop innovative biomedical products and services supporting drug discovery based on cell differentiation...